MacroGenics | MGNX - Equity Capital And Reserves


MacroGenics reported $55.59M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Amgen USD 8.66B 961M Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Genmab DKK 5.85B 96M Dec/2025
Geron USD 225.87M 22.83M Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
J&J USD 78.47B 0 Sep/2025
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
MacroGenics USD 55.59M 11.41M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Xencor USD 635.59M 10.27M Dec/2025